Hodgkin lymphoma nodular lymphocyte-predominant · 8 regimens
Cost vs Efficacy · 2 points
| Regimen | Biomarker | Cost/cycle ↓ | Cycle | PFS ↕ | OS ↕ | Est. cycles | Course cost ↕ | Evidence |
|---|---|---|---|---|---|---|---|---|
R-EPOCH Variant #01 | — | R 28 380 | 21d | — | — | ~6 | ~R 170 281 indirect | — |
R-CHOP Variant #08 | — | R 26 946 | 21d | ~44.4 mo | — | ~6 | ~R 109 868 PFS proxy · indirect | 4 |
R-CVP Variant #01 | — | R 26 502 | 21d | — | — | ~3 | ~R 79 505 PFS proxy · indirect | 1 |
CVP (Vinblastine/Prednisolone) Variant #01 | — | R 3 044 | 21d | — | — | ~3 | ~R 9 131 indirect | — |
ABVD Variant #01 Partial | — | R 2 885 | 28d | — | — | ~2 | ~R 5 770 PFS proxy · indirect | 4 |
EPOCH Variant #01 | — | R 2 138 | 21d | — | — | ~8 | ~R 17 104 indirect | — |
CHOP Variant #20 | — | R 835 | 21d | ~15.5 mo | — | ~6 | ~R 5 011 PFS proxy · indirect | 4 |
Rituximab monotherapy Variant #09 Partial | — | — | 28d | ~20.3 mo | — | ~1 | — | 17 |
8 of 8 regimens shown